Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Tokuyama ( (JP:4043) ) is now available.
Tokuyama Corporation announced its acquisition of JSR Corporation’s in vitro diagnostics and pharmaceutical materials businesses, aiming to enhance its healthcare domain. This strategic move is expected to accelerate product development, generate synergies, and expand market reach in Japan, Korea, and China, positioning Tokuyama as a significant player in the healthcare industry.
More about Tokuyama
Tokuyama Corporation operates in the electronics, healthcare, and environment industries, focusing on products such as in vitro diagnostics and diagnostic pharmaceutical materials. The company aims to expand its healthcare domain and increase its growth business sales to over 60% by 2030.
YTD Price Performance: 9.94%
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.31B
See more data about 4043 stock on TipRanks’ Stock Analysis page.